相关实验视频
Updated: Jan 17, 2026

10:10
Reverse Total Shoulder Arthroplasty
Published on: July 5, 2011
43.8K
ангиотензиногенII受体阻断剂可能降低旋转器袖口修复后粘合性囊炎的风险
Cody S Lee1, Jordan Cook Serotte1, Sai Reddy2
1Department of Orthopaedic Surgery, University of Chicago, Chicago, Illinois, U.S.A.
Arthroscopy, sports medicine, and rehabilitation
|September 22, 2025
概括
血管激素II受体阻塞剂 (ARBs) 可能降低旋转手术后粘合性囊炎 (AC) 的风险. 一旦AC发展,ARBs不会影响需要在麻醉下进行操纵或溶解粘附的需要.
科学领域:
- 整形外科手术 整形外科手术
- 药理学 药理学是指药理学的学科.
- 流行病学 流行病学
背景情况:
- 粘着性囊炎 (AC) 是关节镜旋转手套修复后的潜在并发症.
- 抗纤维菌药物通常被处方,但它们对AC发育的影响尚未得到充分证实.
研究的目的:
- 为了研究常规处方抗纤维素药物与关节镜旋转手套修复后粘合性囊炎 (AC) 的发生率之间的关联.
主要方法:
- 一个回顾性队列研究利用水手数据集 (2010-2022).
- 根据手术前和手术后的药物使用情况 (ARB,ACE抑制剂,COX-2抑制剂,他类药物) 分析了40-65岁的经历旋转手腕修复的患者.
- 在手术后6个月内,通过医疗代码识别了AC的发展,麻醉下的操纵 (MUA) 和关节镜粘附溶解 (LOA).
主要成果:
- 在183,563名患者中,4.62%的人患上了术后AC.
- 处方 angiotensin II 受体阻断剂 (ARB) 的患者表现出发展AC的统计学上显著较低的几率比率 (0.87,P=.04).
- 研究药物与经历MUA或LOA的几率之间没有发现显著的关联.
结论:
- 血管激素II受体抑制剂 (ARBs) 与降低患上粘性囊炎 (AC) 的几率有关.
- 使用ARB并没有影响AC诊断后需要随后的MUA或LOA的可能性.
相关概念视频
Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.5K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.5K
Antihypertensive Drugs: Direct Renin Inhibitors
1.3K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.3K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
942
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
942
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.3K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.3K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
465
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
465
Aortic Regurgitation III: Medical Management
399
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
399

